Webinars for Continuing Education
Basic Tutorials for Those New to the Use of Biomarkers
Accreditations (1 hour each): ACCME, ACCME-NP, ANCC, AOTA, APA, ASWB, JAIPCE, NYSED, NYSED-P (Need to create a free TRAIN account where you can access much more!). Alzheimer's Association and American College of Radiology also have free courses on Amyloid-related imaging abnormalities (ARIA)-see Education page.
* Examining Diagnostic Approaches to Dementia Care Through Use of Biomarkers, Allyson Rosen and Suzanne Schindler, GRECC-Connect (through TRAIN)
* Ethical and Practical Issues in Disclosure of Dementia Risk, Scott Roberts (genetic testing) and Emily Largent (biomarker testing), GRECC-Connect (through TRAIN)
* Biomarker-Based Medical Treatments, Peter Ljubenkcov and Steven Chao (through TRAIN)
* Biomarker Test Readiness for Clinical Use, Nadezda Radoja (FDA rules), Michelle Mielke (challenges to interpretation) - (through TRAIN)
Biofluid Based Biomarkers in Neuropsychiatric Syndromes Series
The First Webinar, October 2021 (with Corinne Fischer & Rawan Tarawneh)
The Disparities Webinar, February 2022 (with Paulo Bertolucci & Ganesh M. Babulal)
The Metabolic Derangements Webinar, June 2022 (with George Perry & Ramit Ravona-Springer)
The Early Career Researcher Webinar, November 2022 (with Fabrizia D'Antonio & Maryam Ghahremani)
The Multi-Modal Biomarker Webinar, February 2023 (with Jennifer R. Gatchel & Fabio H. G. Porto)
The Pharmacological Management Webinar, June 2023 (with Krista L. Lanctôt & Chi Udeh-Momoh)
The Diagnostic Challenges Webinar, November 2023 (with Zahinoor Ismail & Fabricio Oliveira)
The Tenets Webinar, February 2024 (with Julius Popp & William Zeigler Potter)
The Methods Webinar, June 2024 (with Allyson Rosen)
The Prognostic Assessments Webinar, October 2024 (with Dylan Guan & Arturo Xosé Pereiro Rozas)
The Geographic Peculiarities Webinar, February 2025 (with José Guerrero-Cantera & Suzanne Schindler)
The Alzheimer's Association has much more! (https://training.alz.org/ClinicalEducation)
Member Publications
- Schindler et al (2024) Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer's Disease Consensus Statement Nature Reviews Neurology 20, pages 426–439 (2024)
- Oliveira FF et al (2024) Anthropometric and Demographic Features Affect the Interpretation of Cerebrospinal Fluid Biomarkers in Patients with Different Dementia Syndromes and Cognitively Healthy Adults. Neuromolecular Medicine 26 (43) : 1-12.
- Mielke et al (2024) Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease. Alzheimers Dement 20 (11) : 8209-8215.
- Mielke et al (2024) Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease. Alzheimers Dement 20 (11) : 8216-8224.
- Wise-Brown, A., Brangman, S.A., Henderson, J.N., Willis-Parker, M., Monroe, S., Mintzer, J., Grundman, M., Smith, J., Doody, R.S., Lin, H., Assman, B., Rippon, G.A., Gonzales, R., Assuncao, S.S. (2024) Promoting diversity in clinical trials: insights from planning the ALUMNI AD study in historically underrepresented US populations with early symptomatic Alzheimer's disease. eClinicalMedicine, 73 102693.
- Oliveira FF (2024) Shedding Light on the Effects of Blood Pressure on Cognitive Decline and Dementia Risk by Way of Neurobiological Evidence. Journal of Alzheimer's Disease 99, 485-488.
- Rahman-Filipiak et al. (2023) Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials, Alzheimer's and Dementia
- Stites, S. D., & Coe, N. B. (2023). Let's Not Repeat History's Mistakes: Two Cautions to Scientists on the Use of Race in Alzheimer's Disease and Alzheimer's Disease Related Dementias Research. Journal of Alzheimer's Disease: JAD. https://doi.org/10.3233/JAD-220507
- Hampel et al., (2023) Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape, Neuron
- Lingler Toolkit for Biomarker Disclosure (Pittsburgh ADRC)
- Largent et al. (2023) Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum, Neurology.
- Oliveira FF (2023) Looking Behind the Curtain: Patient Stratification According to Genetic or Demographic Factors May Yield Unexpected Results in Studies of Neurodegenerative Diseases. Journal of Alzheimer's Disease 94, 777-780.
- Lewis A. et al (2023) The Association Between Socioeconomic Factors, Race,and Usage of a Specialty Memory Clinic Neurology, doi:10.1212/WNL.0000000000207674
- De Oliveira FF, Miraldo MC, Castro-Neto EF, Almeida SS, Matas SLA, Bertolucci PHF, Naffah-Mazzacoratti MG (2023) Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer's disease. Aging Clinical and Experimental Research 35, 1741-1752.
- Stites, S., D., Vogt, N. M., Blacker, D., Malia, R., Parker, M. W., & The Advisory Group on Risk Evidence Education for Dementia (AGREED). (2022). Patients asking about APOE gene test results? Here's what to tell them. The Journal of Family Practice, 71(4). https://doi.org/10.12788/jfp.0397
- Oliveira FF, Almeida SS, Chen ES, Smith MC, Bertolucci PHF (2022) APOE ε4 Carrier Status as Mediator of Effects of Psychotropic Drugs on Clinical Changes in Patients With Alzheimer's Disease. The Journal of Neuropsychiatry and Clinical Neurosciences 34, 351-360.
- del Campo M, Zetterberg H, Gandy S, Onyike CU, Oliveira F, Udeh-Momoh C, Lleó A, Teunissen CE, Pijnenburg Y (2022) New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimer's & Dementia 18, 2292-2307.
- Erickson, Chin, Ketchum, Jonaitis, Zuelsdorff, Gleason, Clark. Predictors of Willingness to Enroll in Hypothetical Alzheimer Disease Biomarker Studies that Disclose Personal Results. Alzheimer Disease & Associated Disorders: February 04, 2022 - Volume - Issue - doi: 10.1097/WAD.0000000000000490
- Langlois CM, Bradbury A, Wood EM, Roberts JS, Kim SYH, Riviere M-E, Liu F, Reiman EM, Tariot PN, Karlawish J, Langbaum JB (2019) Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimer's & Dementia: Translational Research & Clinical Interventions 5, 705-716.
- Oliveira FF, Bertolucci PHF, Chen ES, Smith MC (2022) Pharmacogenetic Analyses of Therapeutic Effects of Lipophilic Statins on Cognitive and Functional Changes in Alzheimer's Disease. Journal of Alzheimer's Disease 87, 359-372.
- De Oliveira FF (2022) The Viability of Treatment Conditioned to the Pathophysiology of Alzheimer's Disease. In: Santos GAA. Pharmacological Treatment of Alzheimer's Disease: Scientific and Clinical Aspects. Springer, Cham, v. 1, pp. 31-52.
- Qian J, Wolters FJ, Beiser A, Haan M, Ikram MA, Karlawish J, Langbaum JB, Neuhaus JM, Reiman EM, Roberts JS, Seshadri S, Tariot PN, Woods BM, Betensky RA, Blacker D (2017) APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. PLoS Med 14, e1002254.
- van der Schaar, J., Visser, L.N.C., Bouwman, F.H. et al. Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review. Alz Res Therapy 14, 31 (2022). https://doi.org/10.1186/s13195-022-00971-3